The clinical evidence supporting the resection rate using chemo alone is also "good". It has been proven that addition of Oncosil has no statistically significant impact on resection rate. There is no clinical benefit attributable to addition of Oncosil to chemo.
The company has been pushing this "combined action of device and chemo" nonsense for at least 3 years. They either knew it was nonsense and deliberately continued to unscrupulously dupe investors. Or they were not experienced or knowledgeable enough to understand the clinical data and regulatory requirements. Thry don't look so great either way, eh?
Feel free to review all my previous analysis before deciding if they, and you, really should have made better decisions.
OSL Price at posting:
4.9¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)